PD 160170 is a compound developed to inhibit low-risk myelodysplastic syndrome-associated anemia with activities that promote red blood cell transfusion independence and increase hemoglobin.
ChEBI: 5-nitro-6-(2-propan-2-ylphenyl)sulfonyl-8-quinolinamine is a nitro compound and a member of quinolines.
Potent, selective non-peptidic neuropeptide Y 1 receptor antagonist (K i = 48 nM); selective over Y 2 and Y 5 receptors (K i > 10 μ M). Antagonizes NPY-mediated inhibition of cAMP accumulation in SK-N-MC cells (IC 50 = 8.2 nM).
[1] 8-Amino-5-nitro-6-phenoxyquinolines: potential non-peptidic neuropeptide Y receptor ligands